TCGA-39-5039-01A-01R-1443-07
— · cohortSQ1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortSQ1
- subtype
- cohortSQ1
- age_years
- 76
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.580
- CHOLESTEROL_HOMEOSTASIS+0.550
- TNFA_SIGNALING_VIA_NFKB+0.510
- ANGIOGENESIS+0.480
- COAGULATION+0.480
- OXIDATIVE_PHOSPHORYLATION+0.440
- ADIPOGENESIS+0.430
- FATTY_ACID_METABOLISM+0.420
- HYPOXIA+0.420
- P53_PATHWAY+0.420
Top 10 suppressed
- G2M_CHECKPOINT-0.340
- MITOTIC_SPINDLE-0.300
- E2F_TARGETS-0.290
- WNT_BETA_CATENIN_SIGNALING-0.260
- HEDGEHOG_SIGNALING-0.140
- SPERMATOGENESIS-0.080
- KRAS_SIGNALING_DN-0.020
- INTERFERON_ALPHA_RESPONSE+0.030
- NOTCH_SIGNALING+0.040
- INTERFERON_GAMMA_RESPONSE+0.070
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
4 twins match this tumor's tissue · 6 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_8RHPJ740 | EPN | EPN Tumor | 0.879 |
| 2 | BS_8RHPJ740 | Ependymoma NOS | — | 0.877 |
| 3 | 17-026K4_Bladder | — | — | 0.874 |
| 4 | MNG919 | — | — | 0.872 |
| 5 | SRR1347688 | GTEX | — | 0.872 |
| 6 | EPT0508 | EPN | Posterior Fossa EPN | 0.871 |
| 7 | SRR1335688 | GTEX | — | 0.868 |
| 8 | BS_M026T44Q | Meningioma | — | 0.868 |
| 9 | TCGA-BH-A0AY-01A-21R-A00Z-07 | — | A | 0.867 |
| 10 | 4c075dfa-f213-4e97-9c4e-6aac7b8345c7 | — | — | 0.864 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 43 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.580 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.550 | Remibrutinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.510 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.480 | Remibrutinib | — uncovered |
| COAGULATION | 0.480 | Binimetinib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.440 | Remibrutinib | — uncovered |
| ADIPOGENESIS | 0.430 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.420 | Inavolisib | — uncovered |
| HYPOXIA | 0.420 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.420 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.410 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.400 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.390 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.360 | Inavolisib | — uncovered |
| APOPTOSIS | 0.350 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.350 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.350 | Inavolisib | — uncovered |
| MYOGENESIS | 0.350 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.340 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.330 | Inavolisib | — uncovered |